LFCR FY2025 EPS Forecast Boosted by Barrington Research

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Equities research analysts at Barrington Research lifted their FY2025 earnings per share (EPS) estimates for shares of Lifecore Biomedical in a report issued on Wednesday, January 8th. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of ($0.98) per share for the year, up from their previous estimate of ($0.99). The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.99) per share. Barrington Research also issued estimates for Lifecore Biomedical’s FY2026 earnings at ($0.60) EPS and FY2027 earnings at ($0.40) EPS.

Lifecore Biomedical (NASDAQ:LFCR) last issued its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%.

Several other research analysts also recently issued reports on the stock. Stephens restated an “equal weight” rating and set a $6.00 price objective on shares of Lifecore Biomedical in a report on Friday, January 3rd. Craig Hallum boosted their price target on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 22nd.

Lifecore Biomedical Price Performance

NASDAQ:LFCR opened at $6.29 on Friday. The company has a debt-to-equity ratio of 12.90, a current ratio of 1.83 and a quick ratio of 0.80. Lifecore Biomedical has a one year low of $3.68 and a one year high of $8.90. The company has a fifty day moving average price of $7.05 and a 200 day moving average price of $5.82. The stock has a market cap of $232.89 million, a P/E ratio of 78.63 and a beta of 0.98.

Insider Buying and Selling at Lifecore Biomedical

In related news, CEO Paul Josephs acquired 17,000 shares of the firm’s stock in a transaction on Wednesday, January 8th. The shares were bought at an average cost of $5.74 per share, with a total value of $97,580.00. Following the completion of the acquisition, the chief executive officer now owns 559,717 shares of the company’s stock, valued at $3,212,775.58. This trade represents a 3.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 28.21% of the company’s stock.

Hedge Funds Weigh In On Lifecore Biomedical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new position in Lifecore Biomedical in the second quarter valued at about $56,000. Creative Planning bought a new stake in Lifecore Biomedical during the 3rd quarter worth approximately $69,000. Public Employees Retirement System of Ohio bought a new stake in Lifecore Biomedical during the 3rd quarter worth approximately $119,000. Rhumbline Advisers increased its holdings in Lifecore Biomedical by 1,668.5% during the 2nd quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock valued at $138,000 after purchasing an additional 25,378 shares in the last quarter. Finally, Barclays PLC raised its position in Lifecore Biomedical by 301.7% in the 3rd quarter. Barclays PLC now owns 29,944 shares of the company’s stock valued at $147,000 after purchasing an additional 22,489 shares during the last quarter. Institutional investors own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.